Page last updated: 2024-11-12
ripostatin b
Description
ripostatin B: an inhibitor of eubacterial RNA polymerase; isolated from Sorangium cellulosum; a macrocyclic lactone carbonic acid; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 10391134 |
MeSH ID | M0254131 |
Synonyms (2)
Synonym |
ripostatin b |
2-[(3e,6e,9e,12r,14s)-12-hydroxy-14-[(e,2r)-2-hydroxy-5-methyl-7-phenylhept-5-enyl]-10-methyl-2-oxo-1-oxacyclotetradeca-3,6,9-trien-4-yl]acetic acid |
Research Excerpts
Overview
Ripostatin B is a polyketide-derived 14-membered macrolide that acts as an inhibitor of bacterial RNA-polymerase. It is mechanistically distinct from rifamycin-derived RNA-Polymerase inhibitors that are used for tuberculosis treatment.
Excerpt | Reference | Relevance |
"Ripostatin B is a polyketide-derived 14-membered macrolide that acts as an inhibitor of bacterial RNA-polymerase, but is mechanistically distinct from rifamycin-derived RNA-polymerase inhibitors that are in use for tuberculosis treatment." | ( Total Synthesis of Ripostatin B and Structure-Activity Relationship Studies on Ripostatin Analogs. Aínsa, JA; Altmann, KH; Cole, ST; Dedić, D; Glaus, F; Hartkoorn, RC; Kunze, J; Nagaraja, V; Rodrigues, L; Schneider, G; Tare, P, 2018) | 1.53 |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.13 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |